Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway

August 2, 2024

https://www.globenewswire.com/news-release/2024/08/01/2922771/0/en/Intelligent-Bio-Solutions-Partners-with-CenExel-to-Conduct-Clinical-Study-as-Part-of-FDA-510-k-Pathway.html

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq:INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company’s FDA 510(k) clinical study plan.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.